prize winning researchers as well as activists as members. An FDA spokesman did not immediately return a call seeking comment. Among other findings, 36 percent of the FDA scientists said the were "not at all" or only "somewhat" confident that "final decisions adequately assess the safety of a drug." Portions of the survey were published in a March 2003 inspector general's report about the FDA's review process. But the negative opinions often were downplayed in favor of a focus on positive findings, Rest said. A main conclusion in the 2003 report was that "both FDA reviewers and (drug company) sponsors have confidence in the decisions FDA makes," noting 78 percent of FDA scientists felt comfortable with decisions regarding drug effectiveness. The inspector general's report did note that many reviewers felt time-pressured, and 58 percent said the six months allotted for a priority drug review was inadequate. --SP 2159 Local Time 1859 GMT